late
earli
clinic
trial
perform
investig
common
cold
vaccin
larg
administr
formalin
inactiv
singl
rv
serotyp
approach
found
provid
minim
protect
effect
abandon
favour
test
inactiv
multival
vaccin
span
serotyp
although
vaccin
attempt
address
issu
weak
crossserotyp
protect
induc
monoval
vaccin
also
lost
popular
surprisingli
fail
induc
signific
cross
protect
amongst
rv
serotyp
tabl
summaris
studi
perform
human
use
inactiv
rv
prepar
vaccin
suspect
inactiv
rv
vaccin
studi
unfavour
gener
signific
cell
mediat
immun
respons
antibodi
respons
alon
often
gener
situat
insuffici
broad
protect
formalin
treatment
common
method
rv
inactiv
although
altern
method
heat
treatment
pasteuris
low
ph
uv
treatment
also
effect
method
whilst
larg
safe
human
applic
like
destroy
mani
epitop
requir
optim
immun
respons
therefor
impact
neg
vaccin
efficaci
reduc
prepar
immunogen
addit
anoth
potenti
reason
prior
studi
display
limit
success
evid
indic
adjuv
use
amplifi
immun
respons
use
adjuv
would
like
improv
vaccin
efficaci
significantli
howev
time
alum
approv
adjuv
use
human
whilst
sever
other
avail
follow
human
trial
experiment
studi
immunis
anim
rabbit
mice
began
determin
properti
antibodi
cross
reactiv
briefli
encourag
renew
hope
rv
vaccin
crossserotyp
neutralis
antibodi
convincingli
demonstr
tabl
despit
posit
step
rv
vaccin
research
studi
scientif
literatur
virtual
disappear
year
studi
immunis
anim
recombin
rv
capsid
protein
subunit
synthet
peptid
propos
possibl
crossserotyp
protect
antibodi
gener
short
conserv
region
nterminu
capsid
protein
identifi
elicit
crossserotyp
protect
antibodi
other
found
entir
polypeptid
similar
effect
despit
encourag
studi
applic
modern
molecular
analys
formal
demonstr
protect
vaccin
respons
rv
vivo
set
remain
elus
larg
absenc
small
anim
vivo
model
rv
infect
advent
mous
model
human
rv
infect
permit
new
approach
rv
vaccin
develop
specif
rv
challeng
follow
immunis
address
previous
infect
mous
cell
inde
live
mice
human
rv
thought
possibl
due
signific
sequenc
differ
major
group
entri
receptor
human
mous
counterpart
furthermor
lack
sustain
intracellular
viral
replic
mous
cell
despit
minor
group
rv
abil
enter
via
mous
ldl
receptor
mice
transgen
human
improv
method
gener
high
titr
rv
inoculum
allow
intranas
infect
mice
rv
rv
shown
replic
caus
acut
lung
inflamm
well
activ
innat
immun
respons
initi
adapt
immun
respons
immunis
challeng
strategi
subsequ
investig
model
system
provid
basi
evalu
immunolog
correl
protect
rv
vivo
hyperimmunis
mice
inactiv
follow
homolog
intranas
challeng
gener
strong
crossserotyp
neutralis
humor
immun
respons
direct
capsid
protein
although
antibodi
respons
neutralis
vitro
similar
prior
experiment
human
littl
protect
effect
observ
vivo
confirm
use
inactiv
rv
prepar
immunogen
provid
appropri
immunolog
stimul
result
broad
rv
protect
thu
altern
approach
initi
focuss
induct
broadli
reactiv
cell
immun
conserv
region
rv
polyprotein
amongst
type
type
b
strain
identifi
figur
recombin
protein
produc
e
coli
use
immunogen
mice
studi
recombin
deriv
immunogen
vivo
induc
immunogen
rvspecif
antibodi
crossserotyp
system
cellular
immun
respons
furthermor
use
adjuv
combin
induc
crossserotyp
cellular
lymphocyt
produc
cytokin
improv
rvspecif
antibodi
respons
also
shown
immunis
mice
challeng
heterolog
rv
strain
display
enhanc
crossreact
cellular
increas
memori
cell
number
stronger
humor
immun
respons
suggest
broad
crossserotyp
reactiv
obtain
strategi
importantli
immunis
follow
live
rv
challeng
improv
gener
neutralis
antibodi
varieti
rv
serotyp
also
caus
rapid
viru
clearanc
vivo
therefor
repres
use
candid
subunit
rv
vaccin
may
function
gener
signific
crossreact
cell
upon
heterolog
rv
challeng
quickli
stimul
addit
protect
immun
respons
experiment
model
system
rv
infect
translat
human
await
recent
shown
cotton
rat
permiss
infect
display
characterist
similar
mous
rv
infect
model
interestingli
model
prior
immunis
inactiv
rv
via
intramuscular
rout
intranas
rout
produc
signific
neutralis
antibodi
respons
reduc
viral
load
lung
upon
homotyp
challeng
confirm
find
mous
model
experi
prophylact
antibodi
administr
matern
immun
transfer
neonat
protect
although
heterotyp
respons
evalu
use
model
system
addit
mous
model
complement
human
studi
hope
aid
identif
develop
rv
vaccin
larg
unmet
medic
need
result
rv
infect
would
correct
safe
effect
vaccin
major
target
popul
rv
vaccin
would
suffer
chronic
lung
diseas
asthma
chronic
obstruct
pulmonari
diseas
infect
rv
major
precipit
life
threaten
acut
exacerb
requir
hospitalis
would
risk
rv
vaccin
might
exacerb
airway
inflamm
chronic
lung
diseas
sinc
known
rv
infect
asthma
induc
respons
link
lower
airway
diseas
concern
rv
vaccin
might
exacerb
respons
particularli
follow
natur
rv
exposur
thu
favour
rv
vaccin
approach
promot
respons
hypothesis
reset
unbalanc
immun
respons
observ
asthmat
approach
outlin
demonstr
alreadi
mice
whether
vaccin
induc
enhanc
cell
respons
rv
prove
safe
strategi
prevent
rvinduc
diseas
await
confirm
clinic
trial
secondari
popul
would
benefit
rv
vaccin
healthi
individu
broadli
protect
rv
vaccin
could
reduc
burden
common
cold
clearli
popul
receiv
rv
vaccin
would
requir
initi
safeti
efficaci
test
healthi
individu
subsequ
care
monitor
airway
inflamm
follow
natur
experiment
rv
exposur
would
necessari
elimin
possibl
undesir
diseas
augment
occur
follow
challeng
occur
previous
test
formalin
inactiv
rsv
vaccin
infant
attempt
produc
protect
vaccin
rv
fail
due
larg
number
antigen
distinct
serotyp
lack
suitabl
small
anim
model
infect
test
candid
recent
discoveri
previous
unrecognis
clade
rv
complic
nevertheless
studi
immunis
anim
demonstr
signific
crossserotyp
protect
possibl
advent
small
anim
immunis
challeng
model
suitabl
vaccin
candid
evalu
thoroughli
translat
human
quest
rv
vaccin
seem
somewhat
less
forlorn
decad
ago
